...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Nonalcoholic Steatohepatitis is the Most Rapidly Growing Indication for Simultaneous Liver Kidney Transplantation in the United States
【24h】

Nonalcoholic Steatohepatitis is the Most Rapidly Growing Indication for Simultaneous Liver Kidney Transplantation in the United States

机译:非酒精性脂肪性肝炎是美国同时进行肾脏移植的最快速发展的适应症

获取原文
获取原文并翻译 | 示例

摘要

Background. Frequency of liver transplantation (LT) is increasing in nonalcoholic steatohepatitis (NASH) with good post-transplant outcomes. Similar data on simultaneous liver kidney (SLK) transplants are limited. Methods. United Network for Organ Sharing database (2002-2011) queried for deceased donor first LT for primary biliary cirrhosis, primary sclerosing cholangitis, or alcoholic cirrhosis (group I), NASH, and cryptogenic cirrhosis with body mass index greater than 30 (group II), and hepatitis C virus with and without alcohol, hepatitis B virus, and hepatocellular carcinoma (group III). Results. Of 38 533 LT (9495, 3665, and 25 383 in groups I-III, respectively), about 5.6% (N = 2162) received SLK with 584 (6.2%), 320 (8.7%), and 1258 (5%) in groups I-III, respectively. The SLK performed for group II increased from 6.3% in 2002 to 2003 to 19.2% in 2010 to 2011. Similar trends remained unchanged in group I (26.1 to 26.6%) and decreased in group III (67.6 to 54.5%). Five-year outcomes were similar comparing group II versus group I for liver graft (78 vs 74%, P = 0.14) and patient survival (81 vs 76%, P = 0.07). In contrast, kidney graft outcome was worse for group II (70 vs 79%, P = 0.002). Risk of kidney graft loss was over 1.5-fold higher among group II SLK recipients compared to group I after controlling for recipient characteristics. Estimated glomerular filtration rate remained lower in group II compared with group I at various time points after SLK transplantation. Conclusions. The NASH is the most rapidly growing indication for SLK transplantation with poor renal outcomes. Studies are needed to examine mechanisms of these findings and develop strategies to improve renal outcomes in SLK recipients for NASH.
机译:背景。非酒精性脂肪性肝炎(NASH)的肝移植(LT)频率正在增加,并且具有良好的移植后效果。同步肝肾(SLK)移植的相似数据有限。方法。联合器官共享网络数据库(2002-2011)向已故的捐助者查询了原发性胆汁性肝硬化,原发性硬化性胆管炎或酒精性肝硬化(组I),NASH和体重指数大于30的隐源性肝硬化的第一例LT(组II) ,以及含或不含酒精的丙型肝炎病毒,乙型肝炎病毒和肝细胞癌(第三组)。结果。在38533 LT(I-III组中分别为9495、3665和25383)中,约5.6%(N = 2162)的SLK分别为584(6.2%),320(8.7%)和1258(5%)在I-III组中第二组的SLK从2002年至2003年的6.3%增加到2010年至2011年的19.2%。第一组的相似趋势保持不变(26.1%至26.6%),第三组的相似趋势下降(67.6%至54.5%)。比较第二组和第一组的肝移植(78 vs 74%,P = 0.14)和患者存活率(81 vs 76%,P = 0.07),五年结果相似。相比之下,第二组的肾移植结果更差(70%vs 79%,P = 0.002)。在控制接受者特征后,与I组相比,II组SLK接受者的肾移植损失风险高出1.5倍以上。在SLK移植后的不同时间点,II组的肾小球滤过率估计值仍低于I组。结论。 NASH是肾功能不佳的SLK移植发展最快的指征。需要进行研究以检查这些发现的机制,并制定策略以改善NASH的SLK接受者的肾脏结局。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号